Search

Displaying results 4101 - 4110 of 7283 in total
  1. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETIN 1A PHARMA 10MG, PAROXETIN 1A PHARMA 20MG
  2. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  3. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … Food and Drug Administration (FDA) on 18 March 2010.

  4. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

  5. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  6. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.

  7. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

  8. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.

  9. Drug

    Plosaracetam

    go.drugbank.com/drugs/DB21594
    Investigational

    Plosaracetam has a monoisotopic molecular weight of 330.05 Da. … Plosaracetam is a small molecule drug. The usage of the INN stem '-racetam' in the name indicates that Plosaracetam is a piracetam type amide type nootrope agent.

  10. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    Icalcaprant has a monoisotopic molecular weight of 406.2 Da. … Icalcaprant is a small molecule drug. The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist.